|
EE05627B1
(et)
*
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US7357928B2
(en)
*
|
2002-04-08 |
2008-04-15 |
University Of Louisville Research Foundation, Inc. |
Method for the diagnosis and prognosis of malignant diseases
|
|
ES2384168T3
(es)
*
|
2002-04-12 |
2012-07-02 |
Medarex, Inc. |
Procedimientos de tratamiento usando anticuerpos CTLA-4
|
|
CN101628939B
(zh)
*
|
2002-09-06 |
2014-06-25 |
安姆根有限公司 |
治疗性人抗-il-1r1单克隆抗体
|
|
US20040197312A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Marina Moskalenko |
Cytokine-expressing cellular vaccine combinations
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
MXPA05014152A
(es)
|
2003-06-27 |
2006-05-25 |
Abgenix Inc |
Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
|
|
MXPA06000798A
(es)
|
2003-07-22 |
2006-04-07 |
Schering Ag |
Anticuerpos de rg1 y usos de los mismos.
|
|
EP1660537A2
(en)
|
2003-08-14 |
2006-05-31 |
Dyax Corp. |
Endotheliase-2 ligands
|
|
EP1515505A1
(en)
*
|
2003-09-12 |
2005-03-16 |
Siemens Aktiengesellschaft |
Reachability maintainance of a moving network based on temporary name identifiers
|
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
AU2005209909B8
(en)
*
|
2004-02-03 |
2009-01-15 |
The Regents Of The University Of Michigan |
Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
|
|
WO2005092380A2
(en)
*
|
2004-03-26 |
2005-10-06 |
Pfizer Products Inc |
Uses of anti-ctla-4 antibodies
|
|
US7785591B2
(en)
|
2004-10-14 |
2010-08-31 |
Morphosys Ag |
Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
|
|
BRPI0515735A2
(pt)
*
|
2004-11-04 |
2011-10-11 |
Pfizer Prod Inc |
tratamento de combinação de anticorpo de ctla4 e inibidor de aromatase para cáncer de mama, suas composições farmacêuticas e respectivos usos
|
|
AU2006220828A1
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Anti-MAdCAM antibody compositions
|
|
WO2006101691A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
|
|
AU2006227880A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Anti-CTLA4 antibody and indolinone combination therapy for treatment of cancer
|
|
CN117534755A
(zh)
*
|
2005-05-09 |
2024-02-09 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
|
ES2397355T5
(es)
|
2005-06-08 |
2020-11-10 |
Dana Farber Cancer Inst Inc |
Métodos y composiciones para el tratamiento de infecciones persistentes y cáncer por inhibición de la vía de muerte celular programada (PD-1)
|
|
KR20080030656A
(ko)
*
|
2005-07-07 |
2008-04-04 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
|
|
WO2007067959A2
(en)
|
2005-12-07 |
2007-06-14 |
Medarex, Inc. |
Ctla-4 antibody dosage escalation regimens
|
|
CA2647282A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
JP2010534719A
(ja)
*
|
2007-07-27 |
2010-11-11 |
ファイザー・リミテッド |
沈殿化による抗体精製方法
|
|
CN101868241A
(zh)
|
2007-09-28 |
2010-10-20 |
英特瑞克斯顿股份有限公司 |
表达生物治疗分子的治疗基因开关构建物和生物反应器以及它们的应用
|
|
RU2373836C2
(ru)
*
|
2007-12-18 |
2009-11-27 |
Федеральное государственное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова Федерального агентства по высокотехнологичной медицинской помощи" |
Способ оптимизации лечебной тактики при лимфоме ходжкина у детей и подростков
|
|
WO2009089260A2
(en)
*
|
2008-01-08 |
2009-07-16 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
LT2769737T
(lt)
*
|
2009-07-20 |
2017-06-26 |
Bristol-Myers Squibb Company |
Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
|
|
RU2421217C2
(ru)
*
|
2009-09-03 |
2011-06-20 |
Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) |
Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
|
|
WO2012145183A2
(en)
|
2011-04-19 |
2012-10-26 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
|
US9452219B2
(en)
|
2011-06-02 |
2016-09-27 |
University Of Louisville Research Foundation, Inc. |
Anti-nucleolin agent-conjugated nanoparticles
|
|
KR102082363B1
(ko)
|
2012-03-13 |
2020-02-27 |
에프. 호프만-라 로슈 아게 |
난소암의 치료를 위한 조합 치료
|
|
DK2844282T3
(da)
|
2012-05-04 |
2019-07-15 |
Pfizer |
Prostata-associerede antigener og vaccine-baserede immunterapiregimener
|
|
DK2887959T3
(en)
*
|
2012-08-23 |
2019-02-18 |
Agensys Inc |
ANTIBODY-PHARMACEUTICAL CONJUGATES (ADC) BINDING TO 158P1D7 PROTEINS
|
|
WO2014089113A1
(en)
*
|
2012-12-03 |
2014-06-12 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
PL3030575T3
(pl)
|
2013-08-08 |
2018-12-31 |
Cytune Pharma |
Modulokiny oparte na il-15 i domenie sushi il-15r-alfa
|
|
CA2920539C
(en)
|
2013-08-08 |
2024-01-02 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
EP3057990B1
(en)
*
|
2013-10-18 |
2019-09-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
|
|
JP6712952B2
(ja)
*
|
2014-03-31 |
2020-06-24 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
固形腫瘍悪性病変を処置するための、抗ｃｔｌａ−４抗体および／または抗ｐｄ−１抗体と組み合わせた、細菌、細菌産物、および他の免疫調節性実体の使用
|
|
JP6634625B2
(ja)
*
|
2014-05-01 |
2020-01-22 |
株式会社アネロファーマ・サイエンス |
異種ポリペプチド発現カセット
|
|
PH12016502345B1
(en)
|
2014-05-28 |
2023-03-01 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
WO2016033555A1
(en)
|
2014-08-28 |
2016-03-03 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
|
US20170248603A1
(en)
|
2014-10-06 |
2017-08-31 |
Dana-Farber Cancer Institute, Inc. |
Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
|
|
CN108064282A
(zh)
|
2014-10-14 |
2018-05-22 |
哈洛齐梅公司 |
腺苷脱氨酶-2(ada2)、其变体的组合物及使用其的方法
|
|
MX393750B
(es)
|
2014-12-31 |
2025-03-24 |
Checkmate Pharmaceuticals Inc |
Inmunoterapia antitumoral combinada.
|
|
IL292578A
(en)
*
|
2015-02-13 |
2022-06-01 |
Sorrento Therapeutics Inc |
Antibody therapeutics that bind ctla4
|
|
CA3020885A1
(en)
|
2015-05-05 |
2016-11-10 |
Mohammad Tariq MALIK |
Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
|
|
US10144779B2
(en)
|
2015-05-29 |
2018-12-04 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
US9902772B2
(en)
*
|
2015-07-22 |
2018-02-27 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind LAG3
|
|
JP2018523712A
(ja)
*
|
2015-08-18 |
2018-08-23 |
マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. |
腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
|
|
MA44312A
(fr)
|
2015-12-02 |
2018-10-10 |
Agenus Inc |
Anticorps et leurs méthodes d'utilisation
|
|
WO2017165742A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
|
|
WO2017165778A1
(en)
|
2016-03-24 |
2017-09-28 |
Millennium Pharmaceuticals, Inc. |
Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
|
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
|
EA039322B1
(ru)
*
|
2016-04-15 |
2022-01-13 |
Эйдженус Инк. |
Антитела против ctla-4 и способы их применения
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
JP7198666B2
(ja)
*
|
2016-08-26 |
2023-01-04 |
哲治 奥野 |
微小血管血流低減剤およびその利用
|
|
EP4289484A3
(en)
*
|
2016-12-07 |
2024-03-06 |
Agenus Inc. |
Anti-ctla-4 antibodies and methods of use thereof
|
|
WO2018106864A1
(en)
|
2016-12-07 |
2018-06-14 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
SG11202007017PA
(en)
|
2018-02-02 |
2020-08-28 |
Oncoimmune Inc |
Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
|
|
US12246031B2
(en)
|
2018-02-13 |
2025-03-11 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
CN112218892B
(zh)
*
|
2018-03-19 |
2023-04-25 |
上海药明生物技术有限公司 |
新型抗ctla-4抗体多肽
|
|
JP7511478B2
(ja)
|
2018-04-09 |
2024-07-05 |
チェックメイト ファーマシューティカルズ |
ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
|
|
KR20240067973A
(ko)
|
2018-07-11 |
2024-05-17 |
액팀 테라퓨틱스, 인코퍼레이티드 |
조작된 면역자극성 박테리아 균주 및 이의 용도
|
|
CN110092826B
(zh)
*
|
2019-02-28 |
2022-04-15 |
天津大学 |
CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
|
|
WO2021238932A1
(zh)
*
|
2020-05-26 |
2021-12-02 |
百奥泰生物制药股份有限公司 |
多特异性抗体及其应用
|
|
WO2022010537A1
(en)
|
2020-07-10 |
2022-01-13 |
The Regents Of The University Of Michigan |
Gas41 inhibitors and methods of use thereof
|
|
US20230374599A1
(en)
|
2020-10-19 |
2023-11-23 |
Alexander Gusev |
Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
|
|
EP4326321A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|